Fitzek S, Hegemann S, Sauner D, Bönsch D, Fitzek C
Department of Neurology, Friedrich Schiller University Jena, Philosophenweg 3, 07740 Jena, Germany.
Epileptic Disord. 2001 Sep;3(3):147-50.
In placebo-controlled trials, the overall incidence of nonconvulsive status epilepticus was no higher in the tiagabine-treated group than in the placebo-group. Case reports of nonconvulsive status epilepticus under tiagabine suggested a specific role of dose levels, since in these patients symptoms occurred mostly at 40 mg/day or higher. We report a case of complex partial status epilepticus in a patient receiving a low dose of tiagabine and review all 11 case reports of nonconvulsive status epilepticus in patients on tiagabine, with regard to daily doses. Our analysis suggests an individual risk threshold of unknown aetiology.
在安慰剂对照试验中，加巴喷丁治疗组非惊厥性癫痫持续状态的总体发生率并不高于安慰剂组。加巴喷丁治疗下非惊厥性癫痫持续状态的病例报告表明剂量水平有特定作用，因为在这些患者中症状大多出现在每日40毫克或更高剂量时。我们报告了1例接受低剂量加巴喷丁治疗的患者发生复杂部分性癫痫持续状态的病例，并根据每日剂量回顾了加巴喷丁治疗患者中所有11例非惊厥性癫痫持续状态的病例报告。我们的分析提示存在病因不明的个体风险阈值。
